LEO Pharma Closes Dersimelagon Deal as FDA Grants Priority Review for Rare Skin Disease Drug

What happened

LEO Pharma said on Sept. 18 that it has completed its acquisition of worldwide rights to dersimelagon from Tanabe Pharma and that the U.S. Food and Drug Administration has accepted the drug’s New Drug Application for filing with Priority Review. The FDA set an action date by the end of February 2027, according to the Danish dermatology company.

LEO first announced the agreement on Aug. 18. BioPharma Dive described it at the time as a rare skin disease drug purchase worth $435 million.

Deal and drug details

LEO said the terms are unchanged from the August announcement:

• Up to $435 million in upfront and near-term milestone payments.
• Potential further downstream milestones.
• Tiered royalties ranging from double digits to the mid-teens on net sales.

Dersimelagon is an investigational, once-daily oral agonist of the melanocortin 1 receptor (MC1R). It is being developed for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), rare inherited conditions in which patients experience severe pain on exposure to sunlight. The drug has not been approved by the FDA or any other regulator.

Tanabe reported earlier in 2026 that the Phase 3 INSPIRE study met its primary and secondary endpoints with statistically significant and clinically meaningful results, according to LEO’s release.

“We are pleased to have completed the acquisition of dersimelagon and to have reached this important regulatory milestone,” said LEO chief executive Christophe Bourdon.

Why it matters for the sector

The transaction is an example of a late-stage asset changing hands shortly before a regulatory filing. For the buyer, acquiring a drug with positive Phase 3 data and a pending application reduces development risk and shortens the time to potential revenue. For the seller, it converts a program into near-term cash and future royalties without building a commercial organization in the relevant specialty.

Priority Review shortens the FDA’s standard review timeline and is granted to drugs that could offer significant improvements in safety or effectiveness for serious conditions. An action date in early 2027 gives LEO a defined timeline for launch planning.

Rare dermatology has become an area of interest for specialized companies because patient populations are small but concentrated among a limited number of treating physicians, which can make commercialization efficient for a focused sales force. LEO, which has historically concentrated on dermatology, is adding a rare disease product to that franchise.

The oral, once-daily format also matters for patients with chronic conditions. Treatments that are taken at home can be easier to adopt than therapies requiring regular clinic visits, which can influence uptake after approval.

The royalty structure, reaching into the mid-teens, indicates that Tanabe retains a meaningful share of the product’s long-term economics even after selling worldwide rights.

The deal’s economics also show how risk is shared in late-stage transactions. Because the Phase 3 study had already succeeded, a larger share of value could be paid upfront and near term, while downstream milestones and royalties keep the seller aligned with commercial performance. Deals for earlier assets usually push a greater proportion of value into contingent payments.

Specialty dermatology companies have been active acquirers of such assets, since a product that fits an existing sales force can be launched without major new infrastructure.

What to watch

• The FDA decision, expected by the end of February 2027.
• Regulatory filings for dersimelagon in Europe and other markets.
• LEO’s launch preparations and pricing approach in a rare disease population.
• Additional late-stage asset acquisitions by mid-sized specialty pharma companies.

Sources: LEO Pharma press release (via BioSpace), BioPharma Dive

Understanding Erythropoietic Protoporphyria

EPP and XLP belong to a group of conditions called porphyrias, which affect how the body makes heme, a component of hemoglobin. In these two conditions, a substance called protoporphyrin builds up in red blood cells and other tissues.

Protoporphyrin reacts with visible light. When sunlight passes through the skin, it can trigger a reaction that damages nearby tissue, causing intense burning pain, often within minutes of exposure. Visible changes on the skin may be limited even when pain is severe, which can make the condition hard for others to recognize. Many patients organize their lives around avoiding daylight.

Why an MC1R agonist

The melanocortin 1 receptor sits on pigment-producing cells in the skin. When activated, it stimulates production of eumelanin, the darker form of the pigment that helps shield skin from light. An agonist is a molecule that switches a receptor on. Activating MC1R is intended to increase the skin’s natural protection so that patients can tolerate more light before symptoms begin. An injectable implant working through the same receptor is already used in this condition, so a once-daily pill would offer a different way to pursue that mechanism.

How FDA Review Timelines Work

1. Submission. The company submits a New Drug Application with clinical, manufacturing and safety data.
2. Filing decision. The FDA decides, generally within about 60 days, whether the application is complete enough to review.
3. Review designation. Applications receive standard or priority review. Priority review sets a shorter goal, about six months rather than ten, for the FDA to act.
4. Review period. FDA teams evaluate the data, inspect manufacturing facilities and may ask questions or convene advisory committees.
5. Action date. By the goal date, the FDA either approves the drug, with labeling that defines its approved use, or issues a complete response letter describing what must be addressed.

An action date is a target, not a guarantee. The agency can extend its review if a company submits major amendments during the process.

Questions Readers Ask

What does a tiered royalty mean?

The royalty percentage rises as annual sales reach higher thresholds. A range running from double digits into the mid-teens means the seller’s share increases as the product sells more.

What does “met its primary endpoint” mean?

The trial achieved the main measurement it was designed to test, with results unlikely to be due to chance. Secondary endpoints provide additional supporting evidence.

How are rare disease drugs typically commercialized?

Through small, specialized teams that work with the relatively few physicians and centers treating the condition, along with patient support services.

Why buy a drug just before an FDA decision?

Positive Phase 3 data remove much of the development risk, so the buyer pays for a clearer opportunity and can shape launch planning, pricing and the commercial team from the start. The remaining risk centers on the review itself and on how well the product is adopted after approval.

This article is for general information only and is not medical or investment advice. Patients should consult their own physicians.